- About Us
- Partnerships
- Product Portfolio
- Investors
- Patients
- Physicians
- CSR
- Press & Media
EPIDEMIOLOGY
Western dietary habits have made GERD a common disease. Richter and associates reported that 25-40% of Americans experience symptomatic GERD at some point.(1)
Jafri et al. reported that the prevalence of GERD is 24% in Pakistan in 2005.(2)
PATHOPHYSIOLOGY
Schematically, the esophagus, lower esophageal sphincter (LES), and stomach can be envisioned as a simple plumbing circuit as described by Stein and coworkers.(3) The esophagus functions as an antegrade pump, the LES as a valve, and the stomach as a reservoir. The abnormalities that contribute to GERD can stem from any component of the system. Poor esophageal motility decreases clearance of acidic material. A dysfunctional LES allows reflux of large amounts of gastric juice. Delayed gastric emptying can increase the volume and pressure in the reservoir until the valve mechanism is defeated, leading to GERD. From a medical or surgical standpoint, it is extremely important to identify which of these components is defective so that effective therapy can be applied.
NATURAL HISTORY
Gastroesophageal reflux disease (GERD) is associated with a set of typical (esophageal) symptoms, including heartburn, regurgitation, and dysphagia. (However, a diagnosis of GERD based on the presence of typical symptoms is correct in only 70% of patients.) In addition to these typical symptoms, abnormal reflux can cause atypical (extraesophageal) symptoms, such as coughing, chest pain, and wheezing.
Gastroesophageal reflux (GER) is extremely common in healthy infants, in whom gastric fluids may reflux into the esophagus 30 or more times daily.(4) Many, but not all of these reflux episodes result in regurgitation into the oral cavity. The frequency of reflux, as well as the proportion of reflux episodes that result in regurgitation, declines with increasing age, such that physiologic regurgitation or vomiting decreases toward the end of the first year of life, and is unusual in children older than 18 months old.
The American College of Gastroenterology (ACG) published updated guidelines for the diagnosis and treatment of GERD in 2005. According to the guidelines, for patients with symptoms and history consistent with uncomplicated GERD, the diagnosis of GERD may be assumed and empirical therapy begun. Patients who show signs of GERD complications or other illness or who do not respond to therapy should be considered for further diagnostic testing.(5)
A history of nausea, vomiting, or regurgitation should alert the physician to evaluate for delayed gastric emptying.
Patients with GERD may also experience significant complications associated with the disease, such as esophagitis, stricture, and Barrett esophagus. Approximately 50% of patients with gastric reflux develop esophagitis.
SIGN AND SYMPTOMS
The most common symptoms of gastroesophageal reflux disease (GERD) are heartburn (pyrosis), regurgitation, and dysphagia. A variety of potential extraesophageal manifestations have also been described including bronchospasm, laryngitis, and chronic cough. Complications from GERD can arise even in patients who lack typical esophageal symptoms
Other symptoms of GERD include chest pain, water brash, globus sensation, odynophagia, and nausea
DIAGNOSTIC TESTS
The diagnosis of gastroesophageal reflux disease (GERD) can be based upon clinical symptoms alone. In patients presenting with any of the clinical manifestations described above, a presumptive diagnosis of GERD can be made.
Response to antisecretory therapy is not a diagnostic criterion for GERD.(8) A meta-analysis of diagnostic test characteristics found that a response to proton pump inhibitors (PPIs) did not correlate well with objective measures of GERD such as ambulatory pH monitoring.(9)
Upper gastrointestinal endoscopy findings — The findings on upper endoscopy are variable. Upper endoscopy may be normal in patients with GERD, or there may be evidence of esophagitis of varying degrees.
Histology — A review of the literature suggested that about two-thirds of patients who have symptoms of GERD, but have no visible endoscopic findings (i.e. nonerosive reflux disease) have histologic evidence of esophageal injury that responds to acid suppression.
Radiographic findings — Double contrast barium swallow examination is of limited use because of its low sensitivity in patients with mild GERD. Radiologic evaluation is most useful in the detection of peptic stricture.
PATIENT SELECTION FOR TREATMENT
Patients with gastroesophageal reflux disease (GERD) may be managed with a step-up or step-down approach to therapy. The step-up approach involves incrementally increasing the potency of therapy until symptom control is achieved. The step-down approach starts with potent antisecretory agents and then involves incrementally decreasing the potency of therapy until breakthrough symptoms define the treatment necessary for symptom control.
While the optimal strategy is controversial, both have advantages. The step-up approach minimizes the use of proton pump inhibitors (PPIs) and their associated costs and side effects, whereas step-down therapy provides faster symptom relief.
THERAPY CONSIDERATIONS
In patients who are naïve to treatment, we initially recommend lifestyle and dietary modification and, as needed, low-dose histamine 2 receptor antagonists (H2RAs). We suggest concomitant antacids as needed if symptoms occur less than once a week. For patients with continued symptoms despite these measures, we increase the dose of H2RAs to standard dose, twice daily for a minimum of two weeks. Further increases in the dose of H2RA, prolonging the course of treatment, or switching to another H2RA is unlikely to control symptoms.(10, 11) Therefore, if symptoms of GERD persist, we discontinue H2RAs and initiate once-daily PPIs at a low dose and then increase to standard doses if required. Once symptoms are controlled, treatment should be continued for at least eight weeks.
TREATMENT OPTIONS
Life style modifications
The following lifestyle and dietary measures are suggested:(12, 13)
Other measures that have a physiologic basis but have not consistently been demonstrated to improve reflux symptoms include:(14, 15)
Pharmacological
Antacids — As antacids do not prevent GERD, their role is limited to intermittent (on-demand) use for relief of mild GERD symptoms that occur less than once a week.(16)
Surface agents and alginates — Sucralfate (aluminum sucrose sulfate), a surface agent, adheres to the mucosal surface, promotes healing, and protects from peptic injury by mechanisms that are incompletely understood.
Histamine 2 receptor antagonists — Histamine 2 receptor antagonists (H2RAs) decrease the secretion of acid by inhibiting the histamine 2 receptor on the gastric parietal cell. However, the development of tachyphylaxis within two to six weeks of initiation of H2RAs limits their use as maintenance therapy for GERD.(17)
Proton pump inhibitors — Proton pump inhibitors (PPIs) should be used in patients who fail twice-daily H2RA therapy and in patients with erosive esophagitis and / or frequent (two or more episodes per week) or severe symptoms of GERD that impair quality of life.
Surgical
Transthoracic and transabdominal fundoplications are performed for gastroesophageal reflux disease, including partial (anterior or posterior) and circumferential wraps. Open and laparoscopic techniques may be used.
Placement of a device to augment the lower esophageal sphincter is another surgical option.
GOALS OF THERAPY
The goals of treatment are
GUIDELINES
Treatment for GERD is based on guidelines from the prestigious society such as The American College of Gastroenterology (ACG).
To review the guidelines of ACG in the management of GERD, click on the below link
http://gi.org/guideline/diagnosis-and-managemen-of-gastroesophageal-reflux-disease/
LONG TERM MONITORING
Approximately two-thirds of patients with nonerosive reflux disease (NERD), and nearly all patients with erosive esophagitis (EE), relapse when acid suppression is discontinued. However, a trial off of medications should be considered in all patients with gastroesophageal reflux disease (GERD) whose symptoms resolve with acid suppression, except those with severe EE (Los Angeles classification Grade C and D) and Barrett's esophagus.(18) Patients with severe esophagitis should remain on maintenance acid suppression with a proton pump inhibitor (PPI) as they are likely to have recurrent symptoms and complications if acid suppression is decreased or discontinued.(18-21)
PRECAUTIONS
Patient should be instructed on following precautions:
REFERENCES